Latest breakthroughs in cancer research, treatment, and prevention
643 articles
When the DNA-repair gene EXO1 is overproduced, it damages DNA instead of fixing it—exposing a hidden vulnerability in multiple cancers.
A new review reveals how cholangiocarcinoma hijacks the nervous system to invade tissue and suppress immune defenses.
Cell Metabolism has published an erratum (correction notice) for a 2022 paper reporting that cancer cells co-opt nociceptive nerves to survive nutrient stress.
A phase II trial explored ipilimumab, nivolumab, and radiation therapy in advanced HPV-positive oropharyngeal cancer — but was terminated early.
A new strategy combining a TROP2-targeting drug with osimertinib may delay the inevitable resistance that undermines EGFR-mutant lung cancer treatment.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
New research reveals how chronic stress recruits immunosuppressive macrophages from bone marrow into brain tumors, accelerating glioma progression.
A Phase 1/2 NCI trial tested PANVAC vaccinia and fowlpox vaccines plus immune booster sargramostim in advanced colorectal, breast, and ovarian cancers.
A landmark ACSM consensus statement delivers the first evidence-based exercise guidelines for children and adolescents during and after cancer treatment.
PathPrism uses interpretable AI to find spatial biomarkers in colorectal cancer slides, predicting survival, mutations, and chemo benefit.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
